On November 26, 2020, our hospital was certified as a facility capable of providing CAR-T cell therapy (Kymriah®), a new treatment for leukemia and lymphoma.
What is CAR-T cell therapy (Kymriah®)?
CAR-T therapy is an innovative treatment that uses the patient's own immune system to attack cancer by modifying T cells, a type of white blood cell, by gene transfer and administering them to patients.
CAR-T cell therapy is a treatment that uses T cells modified to attack cancer cells by introducing a "chimeric antigen receptor (CAR)". Kymriah® collects T cells from patients, creates CAR-T cells that target the CD19 protein of acute lymphoblastic leukemia, and returns them to the patient.
Flow of Kymriah® treatment
Source: Novartis Pharma K.K. “Kymriah®”website
About facility certification
Preparing Kymriah® requires high quality control at facilities and management of post-administration complications. is possible. We have always built a double-check system and have become an accredited facility. We are working with a medical system that maintains the high quality of the patient's cells.
It is essential that staff of various occupations such as nurses, pharmacists, clinical laboratory technologists, clinical engineers, clerical staff, as well as doctor of Hematology and other departments cooperate and collaborate smoothly.
About facilities
Patients eligible for treatment
Indications for Kymriah®
- Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia (25 years old or younger)
- Relapsed/refractory CD19-positive diffuse large B-cell lymphoma
If you wish to receive treatment for Kymriah®, please consult your doctor and contact our Regional Medical Cooperation Center through a medical institution. (Please note that the Regional Medical Cooperation Center cannot accept direct inquiries from patients and their families.)
You must meet the requirements for treatment with Kymriah®. Ultimately, the department of Hematology at our hospital will make the decision, but if you wish, please tell your current doctor first.
For those receiving Kymriah® treatment and their families (site provided by pharmaceutical company)To medical institutions
When referring a patient who wishes to receive Kymriah® treatment, please confirm the requirements for the treatment target and make an appointment with our Regional Medical Cooperation Center.
Facilities where Kymriah® can be provided (site provided by a pharmaceutical company) Target patient checklist (site provided by pharmaceutical company)
